CAP Business Center
Rue d’Abhooz 31 Zone Industrielle des Hauts-Sarts
Herstal 4040
Belgium
32 4 257 70 21
https://mdxhealth.com
Settore/i:
Settore:
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Michael K. McGarrity | CEO & Executive Director | 533,4k | N/D | 1963 |
Mr. Ron Kalfus | Chief Financial Officer | N/D | N/D | 1974 |
Mr. Joseph Sollee | Executive VP of Corporate Development & General Counsel | N/D | N/D | 1965 |
Mr. John A. Bellano | Chief Commercial Officer | N/D | N/D | 1969 |
Ms. Miriam Reyes | Executive Vice President of Operations | N/D | N/D | 1973 |
Dr. Jason Poole Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
L'ISS Governance QualityScore di MDxHealth SA al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 10.